´ëÇÑÀ§Àå°ü¿Ü°úÇÐȸ Á¦1ȸ Ç׾Ͽ¬±¸ Çмú´ëȸ : 2023-09-02
±³À°ÀÏÀÚ : 2023-09-02
±³À°Àå¼Ò : Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦
±³À°ÁÖÁ¦ : ´ëÇÑÀ§Àå°ü¿Ü°úÇÐȸ Á¦1ȸ Ç׾Ͽ¬±¸ Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑ¿Ü°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀ§Àå°ü¿Ü°úÇÐȸ
´ã´çÀÚ : ±èÁÖ¿¬
¿¬¶ôó : 070-8691-1704
À̸ÞÀÏ : ksgis1012@gmail.com
±³À°Á¾·ù : ¿Ü°ú
Âü¼®¿¹»óÀÎ : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 5 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í ȸ¿ø 2¸¸¿ø/ ºñȸ¿ø 3¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 09:30~09:45 Fluoropyrimidines ³²±ÃÀ±(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 09:45~10:00 Platinums ¹æ°æÇý(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 10:00~10:15 Taxanes and Others ±èÀçÁØ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 10:15~10:30 Target agents & Immunotherapy ÀÌÈ¿¶ô(¿øÀڷº´¿ø)
Åä·Ð 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 10:30~10:50 Åä·Ð ¹ÎÀç¼® / ±è¼º°ï / ÀÌÀºÁÖ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø / °Ç¾çÀÇ´ë / Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 11:10~11:25 Hypersensitivity Reactions and Hematologic Events À̸í¿ø(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 11:25~11:40 Neuropathy and Hand-Foot Syndrome ±èÇüµ·(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 11:40~11:55 Gastro-intestinal Events ÀÌÇÏ¿¹¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 11:55~12:10 QOL after Chemotherapy Treatment and Clinical Trial ¹Ú±â¹ü(°æºÏÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 12:10~12:30 Åä·Ð ±èÀº¿µ / ¹Î»çÈ« / À±»óÀÏ(°¡Å縯ÀÇ´ë / ¿ï»êÀÇ´ë / Ãæ³²ÀÇ´ë)
½Ä»ç 09¿ù 02ÀÏ 5Ãþ Á÷¿ø½Ä´ç 12:30~13:20 Luncheon ()
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 13:20~13:40 Satellite Symposium-Nivolumab for Gastric Cancer ÃÖ¿ø¿µ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 13:40~13:55 Review of chemotherapy guidelines for gastric cancer ±èÀÎÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 13:55~14:10 Response Evaluation Criteria in Solid Tumors (RECIST) ±è¼¸®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 14:10~14:25 Outpatient Chemotherapy: Benefits, Risks, and Costs Áø¼ºÈ£(¿øÀڷº´¿ø)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 14:25~14:40 Neoadjuvant chemotherapy for gastric cancer ÀåÀ¯Áø(°í·ÁÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 14:40~15:00 Åä·Ð Á¤¹Ì¶õ / À±Á¾Çõ / À̼¼Áø(Àü³²ÀÇ´ë / ¼øõÇâÀÇ´ë / ÀüºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 15:20~15:35 Ascites development during adjuvant chemotherapy ±ÇÀαÔ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 15:35~15:50 Complications induced by intraperitoneal chemotherapy ¼¿øÁØ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 15:50~16:05 Preoperative chemotherapy for advanced gastric cancer Á¤ÁöÀ±(±¹±º ¾çÁÖº´¿ø)
±³À°½Ã°£ 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 16:05~16:20 Revisional antreflux surgery ±èµ¿¿í(´Ü±¹ÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ Áß¾Ó´ëÇб³ ±¤¸íº´¿ø 5Ãþ ±èºÎ¼·È¦ 16:20~16:40 Åä·Ð ¿À¼ºÁø / ¼ÛÁ¤È£ / ¹Ú±â¹ü(ÀÎÁ¦ÀÇ´ë / ¾ÆÁÖÀÇ´ë / °¡Å縯ÀÇ´ë)